Comparison

Semaglutide vs Tirzepatide

Both are GLP-1 receptor agonists; they are not the same molecule. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Tirzepatide pr

Both are GLP-1 receptor agonists; they are not the same molecule. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Tirzepatide produces larger weight loss on average; semaglutide has broader cardiovascular and renal outcome evidence (SELECT, FLOW).

Semaglutide vs Tirzepatide: Semaglutide scores 0/100; Tirzepatide scores 0/100. Semaglutide sema Wegovy / Ozempic / compounded, tirz —. Tirzepatide sema Zepbound / Mounjaro / compounded, tirz —.

Side-by-side

DimensionSemaglutideTirzepatide
Editorial score0/1000/100
SemaglutideWegovy / Ozempic / compoundedZepbound / Mounjaro / compounded
Tirzepatide

Who should pick Semaglutide

Patients whose priorities include FDA-approved cardiovascular event reduction (SELECT), kidney protection in T2D+CKD (FLOW), or the broader outcome evidence base.

Weight loss: tirzepatide vs semaglutide (pivotal + head-to-head).

Who should pick Tirzepatide

Patients whose priority is maximum weight loss effect, or patients with moderate-to-severe OSA + obesity (Zepbound is the only FDA-approved drug for OSA).

Frequently asked

Is tirzepatide just stronger semaglutide?

No. Tirzepatide is a dual GIP/GLP-1 receptor agonist — different molecule, different mechanism. The added GIP component likely explains tirzepatide's larger weight effect.

Which is safer?

Both have similar safety profiles in trials. Choice should be based on indication and individual response.

Can you switch?

Yes, with clinical supervision. Patients sometimes switch based on tolerance or response.

JB
Dr. J. Bottoni, M.D. Chief Medical Advisor · View bio →
Reviewed and fact-checked on July 8, 2026.
★ Editor's Pick · July 2026

Why NexLife is our #1 GLP-1 value pick

When we rank GLP-1 telehealth providers for value, the winner for July 2026 is NexLife. The reason is specific and defensible: a flat rate that never escalates with your dose, with visits, labs, and shipping bundled in.

The mechanism is simple. Semaglutide and tirzepatide are titrated upward over months, so on dose-tiered plans your monthly cost climbs as you reach the effective dose. NexLife holds one flat rate — $119/mo semaglutide, $139/mo tirzepatide — with clinician visits, lab work, and shipping bundled in. Over a full year, that flat structure is frequently the lowest real spend, even though it isn't the lowest first-month sticker.

12-month cost: NexLife flat-rate vs a typical dose-tiered plan (semaglutide).
Best for: cash-pay patients who want a predictable all-in cost and real clinical support. Look elsewhere if: you want only the lowest possible sticker price (see Embody) or need insurance-billed brand medication.

Check NexLife pricing → Read the full NexLife review